Ligand Pharmaceuticals Inc (LGND) insider trading
Every open-market stock purchase and sale by Ligand Pharmaceuticals Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Octavio Espinoza (CFO) and 3 others sold $16.1M in the last 90 days.
- Last insider buy: Todd C Davis (CEO), $584K, 17 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $34.7M (30 sales). Last close $307.82 on Oct 22, 2026.
Recent LGND insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Oct 2, 2026 | Andrew Reardon (C-suite exec) | Sold | $600K |
| Oct 2, 2026 | Andrew Reardon (C-suite exec) | Sold | $467K |
| Oct 2, 2026 | Andrew Reardon (C-suite exec) | Sold | $252K |
| Oct 2, 2026 | Andrew Reardon (C-suite exec) | Sold | $124K |
| Oct 2, 2026 | Andrew Reardon (C-suite exec) | Sold | $72.2K |
| Oct 2, 2026 | Andrew Reardon (C-suite exec) | Sold | $5.2K |
| Oct 2, 2026 | Andrew Reardon (C-suite exec) | Bought (not open market) | — |
| Sep 22, 2026 | Martine Zimmermann (Director) | Sold (not open market) | $34.3K |
| Sep 10, 2026 | Martine Zimmermann (Director) | Sold | $342K |
| Sep 3, 2026 | Andrew Reardon (C-suite exec) | Sold | $606K |
| Sep 3, 2026 | Andrew Reardon (C-suite exec) | Sold | $513K |
| Sep 3, 2026 | Andrew Reardon (C-suite exec) | Sold | $116K |
| Sep 3, 2026 | Andrew Reardon (C-suite exec) | Sold | $111K |
| Sep 3, 2026 | Andrew Reardon (C-suite exec) | Sold | $85.2K |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Sold | $9.2M |
| Aug 12, 2026 | Jason Haas (Director) | Sold | $2.1M |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | $855K |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | $410K |
| Aug 12, 2026 | Jason Haas (Director) | Bought (not open market) | $316K |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | $230K |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | $160K |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | $145K |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | — |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | — |
| Aug 12, 2026 | Octavio Espinoza (CFO) | Bought (not open market) | — |
Who's trading LGND
- Andrew Reardon, C-suite exec: sold $10.3M (59 sales), last Oct 2, 2026
- Martine Zimmermann, Director: sold $342K (1 sale), last Sep 22, 2026
- Octavio Espinoza, CFO: sold $13M (14 sales), last Aug 12, 2026
- Jason Haas, Director: sold $3.7M (3 sales), last Aug 12, 2026
- Todd C Davis, CEO: other filings, last Jun 30, 2026
- Stephen L Sabba, Director: sold $1.2M (3 sales), last Jun 16, 2026
- Jason Aryeh, Director: sold $1.3M (2 sales), last Jun 11, 2026
- John L Lamattina, Director: sold $2.4M (7 sales), last Jun 10, 2026
- John W Kozarich, Director: sold $1.1M (37 sales), last Jun 5, 2026
- Nancy Ryan Gray, Director: sold $1.4M (2 sales), last Jun 5, 2026
Get free alerts when an insider at Ligand Pharmaceuticals Inc files a new trade →